223 related articles for article (PubMed ID: 27268469)
1. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.
Wiederhold NP; Patterson TF; Srinivasan A; Chaturvedi AK; Fothergill AW; Wormley FL; Ramasubramanian AK; Lopez-Ribot JL
Virulence; 2017 Feb; 8(2):138-142. PubMed ID: 27268469
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway.
Thangamani S; Maland M; Mohammad H; Pascuzzi PE; Avramova L; Koehler CM; Hazbun TR; Seleem MN
Front Cell Infect Microbiol; 2017; 7():4. PubMed ID: 28149831
[TBL] [Abstract][Full Text] [Related]
3. Repurposing non-antifungal drugs auranofin and pentamidine in combination as fungistatic antifungal agents against
Lin J; Xiao X; Liang Y; Zhao H; Yu Y; Yuan P; Lu S; Ding X
Front Cell Infect Microbiol; 2022; 12():1065962. PubMed ID: 36590591
[TBL] [Abstract][Full Text] [Related]
4. Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains.
Pic E; Burgain A; Sellam A
Med Mycol; 2019 Apr; 57(3):387-390. PubMed ID: 29762783
[TBL] [Abstract][Full Text] [Related]
5. Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity.
Sun N; Li D; Zhang Y; Killeen K; Groutas W; Calderone R
Sci Rep; 2017 Dec; 7(1):17014. PubMed ID: 29209049
[TBL] [Abstract][Full Text] [Related]
6. In vitro synergism between nyasol, an active compound isolated from Anemarrhena asphodeloides, and azole agents against Candida albicans.
Iida Y; Oh KB; Saito M; Matsuoka H; Kurata H
Planta Med; 2000 Jun; 66(5):435-8. PubMed ID: 10909263
[TBL] [Abstract][Full Text] [Related]
7. In view of an optimal gut antifungal therapeutic strategy: an in vitro susceptibility and toxicity study testing a novel phyto-compound.
Metugriachuk Y; Kuroi O; Pavasuthipaisit K; Tsuchiya J; Minelli E; Okura R; Fesce E; Marotta F
Chin J Dig Dis; 2005; 6(2):98-103. PubMed ID: 15904429
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility of Candida albicans in biofilms.
Tobudic S; Kratzer C; Lassnigg A; Presterl E
Mycoses; 2012 May; 55(3):199-204. PubMed ID: 21793943
[TBL] [Abstract][Full Text] [Related]
9. Insights on the anticandidal activity of non-antifungal drugs.
Moraes DC; Ferreira-Pereira A
J Mycol Med; 2019 Sep; 29(3):253-259. PubMed ID: 31399349
[TBL] [Abstract][Full Text] [Related]
10. The activity of ketoconazole in mixed cultures of fungi and human fibroblasts.
Aerts F; De Brabander M; van den Bossche H; van Cutsem J; Borgers M
Mykosen; 1980 Feb; 23(2):53-67. PubMed ID: 6247651
[No Abstract] [Full Text] [Related]
11. Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids.
Lazzarini C; Haranahalli K; Rieger R; Ananthula HK; Desai PB; Ashbaugh A; Linke MJ; Cushion MT; Ruzsicska B; Haley J; Ojima I; Del Poeta M
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507066
[TBL] [Abstract][Full Text] [Related]
12. The effect of Leptospermum petersonii essential oil on Candida albicans and Aspergillus fumigatus.
Hood JR; Burton DM; Wilkinson JM; Cavanagh HM
Med Mycol; 2010 Nov; 48(7):922-31. PubMed ID: 20446888
[TBL] [Abstract][Full Text] [Related]
13. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives.
Nakamoto K; Tsukada I; Tanaka K; Matsukura M; Haneda T; Inoue S; Murai N; Abe S; Ueda N; Miyazaki M; Watanabe N; Asada M; Yoshimatsu K; Hata K
Bioorg Med Chem Lett; 2010 Aug; 20(15):4624-6. PubMed ID: 20573507
[TBL] [Abstract][Full Text] [Related]
15. The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus.
El-Khoury M; Ligot R; Mahoney S; Stack CM; Perrone GG; Morton CO
BMC Res Notes; 2017 Aug; 10(1):364. PubMed ID: 28764751
[TBL] [Abstract][Full Text] [Related]
16. Novel Zinc-Attenuating Compounds as Potent Broad-Spectrum Antifungal Agents with
Cohrt KAO; Marín L; Kjellerup L; Clausen JD; Dalby-Brown W; Calera JA; Winther AL
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439980
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of Fluvastatin Against Candida albicans CYP450 Lanosterol 14 α-demethylase, a Target Enzyme for Antifungal Therapy: An In silico and In vitro Study.
Rana R; Sharma R; Kumar A
Curr Mol Med; 2019; 19(7):506-524. PubMed ID: 31109273
[TBL] [Abstract][Full Text] [Related]
18. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
Kim K; Zilbermintz L; Martchenko M
Ann Clin Microbiol Antimicrob; 2015 Jun; 14():32. PubMed ID: 26054754
[TBL] [Abstract][Full Text] [Related]
19. Aryl-alkyl-lysines: Membrane-Active Fungicides That Act against Biofilms of Candida albicans.
Ghosh C; Yadav V; Younis W; Mohammad H; Hegazy YA; Seleem MN; Sanyal K; Haldar J
ACS Infect Dis; 2017 Apr; 3(4):293-301. PubMed ID: 28238268
[TBL] [Abstract][Full Text] [Related]
20. Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.
Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Tsiouris I; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2008 Jun; 52(6):2196-204. PubMed ID: 18299413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
